DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Triphenyltin hydroxide

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CLD_ABCB11_6hr	Liver	Human	8647	ABCB11	Gain	16.66 μM
CLD_CYP1A1_6hr	Liver	Human	1543	CYP1A1	Gain	32.28 μM
CLD_CYP2B6_6hr	Liver	Human	1555	CYP2B6	Gain	37.48 μM
CLD_CYP3A4_6hr	Liver	Human	1576	CYP3A4	Gain	15.13 μM
CLD_HMGCS2_6hr	Liver	Human	3158	HMGCS2	Gain	20.0 μM
CLD_SULT2A_6hr	Liver	Human	6822	SULT2A1	Gain	8.16 μM
CLD_ABCB11_24hr	Liver	Human	8647	ABCB11	Gain	5.2 μM
CLD_ABCG2_24hr	Liver	Human	9429	ABCG2	Gain	0.1 μM
CLD_CYP1A1_24hr	Liver	Human	1543	CYP1A1	Gain	7.07 μM
CLD_CYP1A2_24hr	Liver	Human	1544	CYP1A2	Gain	7.56 μM
CLD_CYP2B6_24hr	Liver	Human	1555	CYP2B6	Gain	3.97 μM
CLD_CYP3A4_24hr	Liver	Human	1576	CYP3A4	Gain	20.0 μM
CLD_SULT2A_24hr	Liver	Human	6822	SULT2A1	Gain	6.94 μM
LTEA_HepaRG_ABCC2	Liver	Human	1244	ABCC2	Activatory	1.66 μM
LTEA_HepaRG_ADK	Liver	Human	132	ADK	Activatory	15.83 μM
LTEA_HepaRG_BCL2L11	Liver	Human	10018	BCL2L11	Inhibitory	2.98 μM
LTEA_HepaRG_CASP8	Liver	Human	841	CASP8	Activatory	2.42 μM
LTEA_HepaRG_CCND1	Liver	Human	595	CCND1	Activatory	3.65 μM
LTEA_HepaRG_CFLAR	Liver	Human	8837	CFLAR	Activatory	2.39 μM
LTEA_HepaRG_CYP1A1	Liver	Human	1543	CYP1A1	Inhibitory	14.71 μM
LTEA_HepaRG_CYP2B6	Liver	Human	1555	CYP2B6	Activatory	15.56 μM
LTEA_HepaRG_CYP3A5	Liver	Human	1577	CYP3A5	Inhibitory	2.47 μM
LTEA_HepaRG_EGR1	Liver	Human	1958	EGR1	Activatory	8.45 μM
LTEA_HepaRG_FOXO3	Liver	Human	2309	FOXO3	Inhibitory	3.18 μM
LTEA_HepaRG_GADD45A	Liver	Human	1647	GADD45A	Activatory	7.66 μM
LTEA_HepaRG_GCLC	Liver	Human	2729	GCLC	Inhibitory	2.56 μM
LTEA_HepaRG_GCLM	Liver	Human	2730	GCLM	Inhibitory	2.38 μM
LTEA_HepaRG_GSTM3	Liver	Human	2947	GSTM3	Inhibitory	4.64 μM
LTEA_HepaRG_HIF1A	Liver	Human	3091	HIF1A	Inhibitory	9.92 μM
LTEA_HepaRG_IL6R	Liver	Human	3570	IL6R	Activatory	2.1 μM
LTEA_HepaRG_KRT19	Liver	Human	3880	KRT19	Activatory	0.06 μM
LTEA_HepaRG_LPL	Liver	Human	4023	LPL	Inhibitory	1.67 μM
LTEA_HepaRG_PDK4	Liver	Human	5166	PDK4	Inhibitory	3.22 μM
LTEA_HepaRG_PEG10	Liver	Human	23089	PEG10	Activatory	1.89 μM
LTEA_HepaRG_PPP2R4	Liver	Human	5524	PTPA	Inhibitory	2.28 μM
LTEA_HepaRG_SDHB	Liver	Human	6390	SDHB	Inhibitory	2.35 μM
LTEA_HepaRG_TIMP1	Liver	Human	7076	TIMP1	Inhibitory	2.13 μM
LTEA_HepaRG_TNFRSF1A	Liver	Human	7132	TNFRSF1A	Inhibitory	6.66 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
ATG_C_EBP_CIS	Liver	Human	1051	CEBPB	Inhibitory	0.0 μM
ATG_IR1_CIS	Liver	Human	9971	NR1H4	Activatory	0.01 μM
ATG_NRF2_ARE_CIS	Liver	Human	4780	NFE2L2	Activatory	0.02 μM
ATG_PPRE_CIS	Liver	Human	5465\|5467\|5468	PPARA\|PPARD\|PPARG	Activatory	0.0 μM
ATG_NURR1_TRANS	Liver	Human	4929	NR4A2	Gain	0.01 μM
ATG_PPARg_TRANS	Liver	Human	5468	PPARG	Gain	0.02 μM
ATG_RXRb_TRANS	Liver	Human	6257	RXRB	Gain	0.01 μM
BSK_3C_HLADR	Vascular	Human	3122	HLA-DRA	Inhibitory	0.05 μM
BSK_4H_Pselectin	Vascular	Human	6403	SELP	Inhibitory	2.23 μM
BSK_BE3C_HLADR	Lung	Human	3122	HLA-DRA	Inhibitory	2.15 μM
BSK_BE3C_IL1a	Lung	Human	3552	IL1A	Inhibitory	3.97 μM
BSK_BE3C_MMP1	Lung	Human	4312	MMP1	Inhibitory	2.2 μM
BSK_BE3C_tPA	Lung	Human	5327	PLAT	Inhibitory	12.27 μM
BSK_CASM3C_HLADR	Vascular	Human	3122	HLA-DRA	Inhibitory	3.97 μM
BSK_hDFCGF_EGFR	Skin	Human	1956	EGFR	Inhibitory	7.06 μM
BSK_hDFCGF_IP10	Skin	Human	3627	CXCL10	Inhibitory	0.07 μM
BSK_KF3CT_IL1a	Skin	Human	3552	IL1A	Inhibitory	0.05 μM
BSK_KF3CT_IP10	Skin	Human	3627	CXCL10	Inhibitory	0.06 μM
BSK_LPS_MCSF	Vascular	Human	1435	CSF1	Inhibitory	0.14 μM
BSK_LPS_PGE2	Vascular	Human	5732	PTGER2	Inhibitory	20.0 μM
BSK_SAg_CD40	Vascular	Human	958	CD40	Inhibitory	0.14 μM
BSK_SAg_CD69	Vascular	Human	969	CD69	Inhibitory	1.73 μM
NVS_ADME_hCYP2C8		Human	1558	CYP2C8	Loss	2.93 μM
NVS_ADME_hCYP4F12		Human	66002	CYP4F12	Loss	1.69 μM
NVS_ENZ_hBACE		Human	23621	BACE1	Loss	30.63 μM
NVS_ENZ_hHDAC6		Human	10013	HDAC6	Loss	5.22 μM
NVS_GPCR_g5HT4	Brain	Guinea pig	100135548	Htr4	Loss	6.99 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	6.08 μM
NVS_GPCR_hAdra2A		Human	150	ADRA2A	Loss	8.88 μM
NVS_GPCR_hDRD1		Human	1812	DRD1	Loss	0.13 μM
NVS_GPCR_hM1		Human	1128	CHRM1	Loss	6.85 μM
NVS_GPCR_hM3		Human	1131	CHRM3	Loss	25.0 μM
NVS_GPCR_hOpiate_D1		Human	4985	OPRD1	Loss	0.12 μM
NVS_GPCR_rmMGluR1	Brain	Rat	24414	Grm1	Loss	8.34 μM
NVS_GPCR_rOpiate_NonSelective	Brain	Rat	25601	Oprm1	Loss	46.66 μM
NVS_TR_rSERT	Brain	Rat	25553	Slc6a4	Loss	9.8 μM
CPHEA_Stoker_NIS_Inhibition_RAIU	Kidney	Human	6528	SLC5A5	Loss	3.78 μM
TOX21_AR_BLA_Agonist_ratio	Kidney	Human	367	AR	Gain	20.43 μM
TOX21_AR_BLA_Antagonist_ratio	Kidney	Human	367	AR	Loss	0.1 μM
TOX21_ERa_BLA_Agonist_ratio	Kidney	Human	2099	ESR1	Gain	40.7 μM
TOX21_GR_BLA_Agonist_ratio	Cervix	Human	2908	NR3C1	Gain	9.01 μM
TOX21_PPARg_BLA_Agonist_ratio	Kidney	Human	5468	PPARG	Gain	18.4 μM
TOX21_TR_LUC_GH3_Antagonist	Pituitary gland	Rat	7067\|7068	THRA\|THRB	Loss	0.07 μM
TOX21_VDR_BLA_Antagonist_ratio	Kidney	Human	1591\|7421	CYP24A1\|VDR	Loss	0.1 μM
TOX21_RORg_LUC_CHO_Antagonist	Ovary	Chinese hamster	6097	RORC	Loss	0.09 μM
TOX21_RAR_LUC_Antagonist	Embryo	Mouse	5914	RARA	Loss	0.1 μM
TOX21_AP1_BLA_Agonist_ratio	Cervix	Human	2353\|3725	FOS\|JUN	Gain	14.32 μM
TOX21_TSHR_HTRF_Antagonist_ratio	Kidney	Human	7253	TSHR	Loss	10.97 μM
TOX21_TRHR_HEK293_Agonist	Kidney	Human	7201	TRHR	Gain	4.33 μM
TOX21_TRHR_HEK293_Antagonist	Kidney	Human	7201	TRHR	Loss	1.63 μM
TOX21_p450_CYP3A4_Antagonist		Human	1576	CYP3A4	Loss	9.93 μM
TOX21_p450_CYP2D6_Antagonist		Human	1565	CYP2D6	Loss	3.22 μM
TOX21_p450_CYP2C19_Antagonist		Human	1557	CYP2C19	Loss	6.2 μM
TOX21_p450_CYP2C9_Antagonist		Human	1559	CYP2C9	Loss	2.48 μM
TOX21_p450_CYP1A2_Antagonist		Human	1544	CYP1A2	Loss	26.37 μM
TOX21_hERG_U2OS_Antagonist	Bone	Human	3757	KCNH2	Loss	2.31 μM
TOX21_GNRHR_HEK293_Agonist	Kidney	Human	2798	GNRHR	Gain	26.42 μM
TOX21_KISS1R_HEK293_Agonist	Kidney	Human	84634	KISS1R	Gain	41.99 μM
TOX21_KISS1R_HEK293_WT	Kidney	Human	84634	KISS1R	Gain	28.74 μM

No ToxCast endpoints for intended target type: Molecular messenger

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist	Bone	Human	367	AR	Loss	0.0 μM
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist	Bone	Human	367	AR	Loss	0.0 μM
APR_HepG2_StressKinase_1hr	Liver	Human	3725	JUN	Inhibitory	0.11 μM
OT_AR_ARSRC1_0960	Kidney	Human	367\|6714	AR\|SRC	Gain	0.03 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	0.01 μM
ACEA_AR_antagonist_80hr	Prostate	Human	367	AR	Loss	0.13 μM
TOX21_HSE_BLA_Agonist_ratio	Cervix	Human	3297	HSF1	Gain	11.72 μM
TOX21_p53_BLA_p1_ratio	Intestinal	Human	7157	TP53	Gain	8.02 μM
TOX21_FXR_BLA_Agonist_ratio	Kidney	Human	9971	NR1H4	Gain	13.47 μM
TOX21_FXR_BLA_Antagonist_ratio	Kidney	Human	9971	NR1H4	Loss	0.1 μM
TOX21_PPARd_BLA_Agonist_ratio	Kidney	Human	5467	PPARD	Gain	7.11 μM
TOX21_PPARd_BLA_Antagonist_ratio	Kidney	Human	5467	PPARD	Loss	0.06 μM
TOX21_PPARg_BLA_Antagonist_ratio	Kidney	Human	5468	PPARG	Loss	0.01 μM
TOX21_p53_BLA_p2_ratio	Intestinal	Human	7157	TP53	Gain	3.32 μM
TOX21_p53_BLA_p3_ratio	Intestinal	Human	7157	TP53	Gain	10.03 μM
TOX21_p53_BLA_p4_ratio	Intestinal	Human	7157	TP53	Gain	5.88 μM
TOX21_p53_BLA_p5_ratio	Intestinal	Human	7157	TP53	Gain	23.93 μM
TOX21_ESRE_BLA_Agonist_ratio	Cervix	Human	22926	ATF6	Gain	47.51 μM
TOX21_NFkB_BLA_agonist_ratio	Cervix	Human	4790	NFKB1	Gain	8.33 μM
TOX21_HDAC_LUC_Antagonist	Colon	Human	3065	HDAC1	Loss	10.78 μM
TOX21_HRE_BLA_Agonist_ratio	Cervix	Human	3091	HIF1A	Gain	7.86 μM
TOX21_SHH_3T3_GLI3_LUC_Antagonist	Embryo	Mouse	6469	SHH	Loss	0.05 μM
TOX21_p53_BLA_p7_ratio	Intestinal	Human	7157	TP53	Gain	10.4 μM

ToxCast endpoints for intended target type: Cellular

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
TOX21_CASP3_HEPG2	Liver	Human	836	CASP3	Gain	0.1 μM
TOX21_CASP3_CHO	Ovary	Chinese hamster	836	CASP3	Gain	0.1 μM

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.